Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: TG4001

    Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024

    2023 half year results and business update

    Published 20 September 2023
    Categorized as 2023, BT-001, BT-001 (EN), dates, dates, Press release, TG4001, TG4001, TG4050, TG6050-en, TG6002

    Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

    C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

    Published 29 August 2023
    Categorized as 2023, Publication, publication HP en, TG4001, TG4001

    Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023

    Transgene immunological data demonstrating that TG4001 can induce T-cell responses

    Published 5 June 2023
    Categorized as 2023, dates, dates, Press release, TG4001, TG6002

    Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

    Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting

    Published 26 May 2023
    Categorized as 2023, dates, dates, Invir.IO, Myvac, Press release, TG4001, TG4050, TG6002

    Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

    TRANSGENE announces positive interim analysis results of Phase II trial evaluating TG4001

    Published 2 November 2022
    Categorized as 2022, 2022, Press release, dates, Invir.IO, Press release, TG4001, TG4001

    R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

    TRANSGENE R&D DAY

    Published 27 September 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

    First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers

    20210624 Transgene TG4001.12 FPI EN

    Published 24 June 2021
    Categorized as 2021, Press release, TG4001, TG4001

    Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

    20210310 Transgene TG4001 randomized Phase II EN

    Published 10 March 2021
    Categorized as 2021, Press release, TG4001, TG4001

    Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC

    Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication

    Published 26 January 2021
    Categorized as 2021, Publication, TG4001, TG4001

    Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020

    20201203 – TG4001 mini oral prez ESMO IO EN

    Published 3 December 2020
    Categorized as 2020, Press release, TG4001, TG4001

    Posts navigation

    Page 1 Page 2 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2023 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo